Appointment part of company’s ambitious global growth strategy
CN Bio, one of the world’s leading Organ-on-a-Chip companies has appointed Dr Samantha Macro as Chief Financial Officer. Dr Macro joins CEO, Dr Paul Brooks, on the executive board to guide key commercial and strategic initiatives, increase revenue and shape the company’s growth trajectory.
CN Bio designs and manufactures single-and multi-organ microphysiological systems.
Dr Macro’s appointment is CN Bio’s third leadership-level appointment in the past six months, as the company continues to expand during this next phase of commercial development. Bringing extensive financial industry experience, including over 15 years in life sciences, Dr Macro will play a key role in guiding and executing the decisions which will expand use of CN Bio’s Organ-on-a-Chip products in key markets worldwide.
Disruptive OOC solutions
“CN Bio’s OOC solutions are disruptive within the sector; capable of accurately and efficiently predicting human responses to medicines. As its growing range of products and services continue to gain traction across global markets, I look forward to working closely with the leadership team and leveraging my commercial insight to push the company to reach its full potential,” Dr Macro commented.
Most recently, Dr Macro was VP of Finance at Mestag Therapeutics, where she was a core part of the leadership team that secured the company’s successful $45 million seed financing round. Prior to this, she was Global Head of Finance at Horizon Discovery, during which time she supported strategic and M&A initiatives while preparing for a NASDAQ listing. She was a core part of the team that supported the pre- and post-acquisition associated with the sale of the Group to PerkinElmer (now Revvity). She has also held various leadership roles at the Johnson Matthey Pharma division, and across multiple innovative medicine units at AstraZeneca. Ahead of transitioning into life sciences, Samantha qualified as a chartered accountant at PwC and held senior roles at PwC and Aviva. She has an MBA and PhD from Loughborough University Business School.
“[Dr Macro] has a proven track record in fundraising and will bring valuable M&A experience to the company. We have reached a critical phase in the commercialisation of our OOC technology, and Samantha will be instrumental in reaching our business goals and executing our continued growth strategy,” said Dr Brooks.